Clara [for Kelly Shi]'s questions to Syndax Pharmaceuticals Inc (SNDX) leadership • Q1 2025
Question
Representing Kelly Shi from Jefferies, Clara asked if the rate of patients receiving stem cell transplants after Revuforj treatment is similar to clinical trials and about the current use of Revuforj as maintenance therapy.
Answer
CEO Michael Metzger responded that it is still early in the launch and current information is anecdotal. He conveyed that physicians are reporting that they are successfully taking patients to transplant, which is encouraging. He also noted an expectation for patients to resume Revuforj as maintenance therapy post-engraftment, with more concrete data expected as the launch matures.